For Immediate Release FIRST PATIENT COMPLETES FOUR YEARS IN DMX-200 CLINICAL PROGRAM Highlights • Significant milestone achieved as first patient completes 2-years in the DMX-200 Open Label Extension (OLE) study, in addition to completing the 2-year ACTION3 Phase 3 trial • The milestone...